Sifalimumab Biosimilar - Research Grade

Human

Interferon Alpha 1

>1mg/ml

Human IgG1 Kappa

Bifarcept Biosimilar - Research Grade (ICH5401), Faralimomab Biosimilar - Research Grade (ICH5543), Rontalizumab Biosimilar - Research Grade (ICH5835)

https://www.imgt.org/mAb-DB/

ICH3002

P0DY56

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-interferon-alpha antibody sifalimumab, supplied strictly for research use only. It is a fully human IgG1 kappa immunoglobulin built to recognise interferon-alpha, matching the originator drug's target specificity, and is not the clinical medicine, nor is it intended for any human or veterinary use. Because it reproduces the binding activity of the originator without therapeutic formulation, it is useful as a reference reagent for laboratory work: as a positive control in binding and neutralisation assays, as a tool to probe type I interferon signalling, as a benchmark in comparability or bioanalytical method development, and as a starting point in antibody engineering, ADCC characterisation, or antibody-drug-conjugate development workflows. It is produced at research grade with low endotoxin (<1 EU/mg, with an ultra-low <0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support in-vitro assays, cell-based systems, and preclinical model standardisation. Reproducible lot-to-lot performance makes it suitable for extended or scaled experimental programmes. Interferon alpha-1 (IFN-alpha1) is a member of the type I interferon family, a group of secreted cytokines central to innate antiviral defence. It is produced by many cell types, notably plasmacytoid dendritic cells, in response to viral nucleic acids and other danger signals. Like other IFN-alpha subtypes, it signals by binding the shared type I interferon receptor, a heterodimer of IFNAR1 and IFNAR2, triggering the JAK-STAT pathway (via JAK1 and TYK2) and inducing hundreds of interferon-stimulated genes. These drive antiviral, antiproliferative, and immunomodulatory effects, including enhanced dendritic cell maturation, natural killer and cytotoxic T cell activity, and MHC upregulation. Dysregulated type I interferon activity, often described as an "interferon signature," is implicated in autoimmune conditions such as systemic lupus erythematosus and myositis, which is why neutralising IFN-alpha has been pursued therapeutically.

IFN-alpha-1, Interferon alpha-D, LeIF D, IFNA1

Detects human IFNA1

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.